Kiadis Pharma Archives

Investment Gap finance savings currency train bridge

News and Trends 23 Feb 2021

European Cancer Deals Increasingly Focus on Natural Killer Cells

Natural killer cells are becoming a hot topic in the booming cancer cell therapy scene, with the field’s latest big deal being a €640M licensing agreement between the French biotech Cellectis and US company Cytovia. T-cell immunotherapies like CAR T-cell therapy have revolutionized cancer treatment in recent times. However, they have a significant disadvantage. The […]

February 23, 2021 - 6 minutesmins - By Kostas Vavitsas

News and Trends 17 Dec 2020

Covid-19 Leaves Lasting Impact on Hematology at ASH 2020 Conference

Under the heavy shadow of the Covid-19 pandemic, last week’s annual conference of the American Society of Hematology (ASH) displayed the achievements of many innovative treatments for blood conditions, including gene and cell therapies. A sweeping new wave of Covid-19 infections that is forcing new lockdowns across the northern hemisphere is already reshaping the biotech […]

December 17, 2020 - 6 minutesmins - By Victor Kotsev

News and Trends 3 Nov 2020

Kiadis’ Natural Killer Cell Therapies Earn €308M Acquisition by Sanofi

The French big pharma Sanofi has offered €308M to acquire the Dutch firm Kiadis Pharma and get hold of cancer cell therapies based on a type of immune cells called natural killer cells. The offer comes not long after Sanofi inked a deal worth up to €857.5M to license a preclinical-stage cancer cell therapy from […]

November 3, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 13 Jul 2020

Sanofi Enlists Cell Therapy Firm Kiadis in €875M Immuno-Oncology Deal

The Dutch biotech Kiadis Pharma has licensed an off-the-shelf cell therapy program to the pharma giant Sanofi for up to €857.5M in a deal aiming to develop a combination immunotherapy for the blood cancer multiple myeloma. The preclinical-stage cell therapy that Kiadis licensed is based on genetically modifying donor immune cells called natural killer cells, […]

July 13, 2020 - 3 minutesmins - By David Wilson

bone marrow transplant blood cancer kiadis pharma cell therapy

News and Trends 13 Nov 2019

Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial

The Dutch company Kiadis Pharma has discontinued the development of a cell therapy in blood cancer, laid off half of its workforce, and switched focus to other, less advanced cell therapy programs. The abandoned phase III trial was testing Kiadis Pharma’s lead cell therapy for the treatment of graft-versus-host disease, a complication of stem cell […]

November 13, 2019 - 2 minutesmins - By Jonathan Smith

kiadis pharma bone marrow transplant cell therapy

News and Trends 3 Jun 2019

Dutch Company Raises €28M to Push Cancer Cell Therapy to European Market

The Dutch Kiadis Pharma has raised €27.6M in a private placement to fund the clinical development of immune cell therapies treating blood cancer. The money will fund phase III trials of Kiadis’ lead candidate cell therapy for blood cancer, aimed to get European approval by the end of 2019. In addition, the cash will boost […]

June 3, 2019 - 2 minutesmins - By Jonathan Smith

In Depth 23 Jan 2018

Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the Loudest?

Although biotech may seem like an industry that has only just gotten started, it was already up and running before the turn of the century. We took a look back at the pre-2000 companies to see how they’re faring. According to our biotech map, there were 219 biotechs in Europe in 1999. Today, our map […]

January 23, 2018 - 10 minutesmins - By Alex Dale

News and Trends 4 Dec 2017

Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching

Kiadis Pharma starts Phase III trials with ATIR101, a therapy that could make half-matched donors suitable for bone marrow transplant to treat blood cancer. From its Amsterdam headquarters, Kiadis Pharma is developing a technology that could solve one of the biggest problems of bone marrow transplantation: finding a donor match. Currently, a bone marrow transplant is […]

December 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2017

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

The FDA has backed Kiadis Pharma’s lead blood cancer product by granting it the Regenerative Medicine Advanced Therapy designation. Kiadis Pharma, based in Amsterdam, develops products to make bone marrow transplants for the treatment of blood cancer and inherited blood disorders safer and more effective. Their lead T cell immunotherapy candidate, ATIR101, reduces the risk of complications, and […]

September 20, 2017 - 2 minutesmins - By Alex Dale

Interview 22 May 2017

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer

Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved. Arthur Lahr has been part of the Dutch biotech scene for over 15 years now. The former Chief Strategy Officer of Crucell, which was sold to J&J in 2011, is now […]

May 22, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Apr 2017

BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD). Kiadis‘ MAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric Investigation Plan for its lead product ATIR101, the MAA was just a matter of time. Based in Amsterdam, […]

April 26, 2017 - 1 minutemin - By Melanie De Almeida

News and Trends 15 Dec 2016

Curing Cancer with Safer Transplants: UK Approval to start Clinical Trials

Kiadis Pharma has received approval to test in the UK an immune therapy to address the big challenges of bone marrow transplants, currently the only cure for blood cancers. Kiadis Pharma, based in Amsterdam, is working on therapies to improve the outcome of hematopoietic stem cell transplantation (HSCT), a common treatment for multiple types of […]

December 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us